Biotechnology and imaging agent developer Kereos has signed a licensing agreement with Dow Chemical. The deal gives both companies access to each others' patent portfolios for the development and commercialization of targeted imaging agents.
The agreement builds on a relationship in place between the two firms since April 2003, under a National Cancer Institute contract involving Kereos, Dow, Royal Philips Electronics, and researchers at Barnes-Jewish Hospital and Washington University in St. Louis. Under the terms of the new deal, Kereos obtains commercial rights to the chelating molecules, and to a chelate technology previously developed by Dow.
The agreement also allows Dow to use the molecules created under the collaboration in other applications, according to Kereos of St. Louis and Dow of Midland, MI. Financial terms of the agreement were not disclosed.
By AuntMinnie.com staff writers
September 23, 2004
Related Reading
Kereos, Bristol-Myers Squibb to collaborate in molecular imaging, March 3, 2004
Philips, Dow, Kereos win NCI imaging contract, April 25, 2003
Copyright © 2004 AuntMinnie.com
